X-ZELL to present at EMUC18

Amsterdam, November 2018 – X-ZELL CEO, Dr Sebastian Bhakdi, has been invited to join the 2018 European Multidisciplinary Congress on Urological Cancers (#EMUC18) in Amsterdam next month as a plenary speaker.

Dr Bhakdi’s addition to the Congress’ high-profile program comes on the back of his ground-breaking research into the utility of ultra-rare Circulating Endothelial Cells (tCEC) for the early detection of clinically significant prostate cancer in whole blood.

A pilot study Dr Bhakdi presented at the Asia-Pacific Prostate Cancer Conference (APCC) in August had demonstrated that detection of these new biomarkers could prevent seven in ten unnecessary biopsies – making them one of the most promising new leads in early cancer detection worldwide.

In Amsterdam, Dr Bhakdi will reveal how he and his team at Siriraj Hospital in Bangkok, Thailand, have managed to isolate and visualise tCEC from whole blood despite previous research noting the elusive cells were undetectable in clinical routine, and give an update on a 1,000-patient validation study that is currently nearing completion.

He will also outline why tCEC outperform existing biomarkers such as Circulating Tumour Cells (CTC) or tumour-derived DNA in clinical practice, and how they could reshuffle the entire diagnostic decision-making process as we know it.

Dr Bhakdi will speak as part of Plenary Session 1 on Friday, 9 November 2018, at 9:30am in the Main Auditorium.

More info via www.emuc18.org.


Media Contact:
Sebastian Grote
Head of Marketing & Communications

Next-generation cytology

© 2024 X-ZELL Biotech Pte. Ltd.

Find Us